Eli Lilly

Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis

Read more

Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020: CFO

Read more

Lilly’s pancreatic cancer treatment fails late-stage study

Read more

Lilly’s targeted RET drug shrinks tumours in lung cancer trial

Read more

China expands drug bulk-buy programme, puts pressure on pharma firms

Read more